Spondyloepimetaphyseal Dysplasia, Short Limb–Abnormal Calcification Type (SMED-SL/AC): A Comprehensive Disease Report

Disease category: Mendelian (monogenic skeletal dysplasia) **Causal gene:** *DDR2* (Discoidin Domain Receptor 2) **Inheritance:** Autosomal recessive **Key identifiers:** OMIM #271665 (phenotype), OMIM *191311 (gene); ORPHA:1425; MONDO:0009642; HGNC:2968; UniProt Q16832

Summary

Spondyloepimetaphyseal dysplasia, short limb–abnormal calcification type (SMED-SL/AC, also "spondylo-meta-epiphyseal dysplasia, short limb–hand type") is an ultra-rare, autosomal recessive congenital skeletal dysplasia. It is defined clinically by severe disproportionate short-limbed short stature, a distinctive facial gestalt (flat/short face, short nose with wide nasal bridge, long philtrum, ocular hypertelorism, micro-/retrognathia, narrow chest), platyspondyly, markedly abnormal metaphyses and epiphyses, short ribs, and the hallmark feature of premature/abnormal calcification. The disorder is caused by **biallelic loss-of-function variants in *DDR2***, the gene encoding Discoidin Domain Receptor 2, a collagen-activated receptor tyrosine kinase (RTK). This report synthesizes six confirmed findings and 18 reviewed papers into a coherent mechanistic and clinical account.

The central mechanistic insight is that DDR2 is a collagen sensor required for **growth-plate chondrocyte proliferation**. Fibrillar collagen binding to the extracellular discoidin (DS) domain triggers a slow, sustained receptor autophosphorylation cascade — Src-mediated phosphorylation of the activation loop (Tyr-740), intramolecular cis-autophosphorylation, and recruitment of Shc signaling complexes — that drives chondrocyte proliferation in the resting and proliferating zones of the growth plate and in Gli1-positive skeletal progenitors. SMED-SL/AC variants abolish this signaling either by impairing collagen binding (discoidin-domain

variants such as R124W) or by disabling catalysis (kinase-domain variants T713I, I726R, R752C, and splice/nonsense alleles). The downstream consequence — reduced chondrocyte proliferation — was demonstrated directly in *Ddr2*-deficient mice, which develop dwarfism, shortened long bones, and craniofacial defects that recapitulate the human phenotype.

A striking allelic contrast illuminates DDR2 biology: **activating** DDR2 variants (p.Leu610Pro, p.Tyr740Cys) cause the mechanistically opposite disorder **Warburg-Cinotti syndrome** (progressive corneal neovascularization, keloids, acro-osteolysis). DDR2 thus behaves as a bidirectional signaling rheostat, with loss-of-function producing SMED-SL/AC and gain-of-function producing Warburg-Cinotti syndrome. There is no disease-specific therapy; management is supportive, combined with genetic counseling and prenatal/carrier testing in at-risk (frequently consanguineous) families.

Key Findings

Finding 1 — SMED-SL/AC is caused by biallelic loss-of-function *DDR2* variants

The genetic basis of SMED-SL/AC was established by homozygosity mapping in a consanguineous cohort. Bargal et al. (2009) studied 6 patients from 5 consanguineous Arab Muslim families and mapped the disease to a 2.4-Mb interval on chromosome 1q23, identifying four *DDR2* mutations clustered in the sequence encoding the tyrosine kinase domain: three missense variants — c.2254C>T (p.R752C), c.2177T>G (p.I726R), c.2138C>T (p.T713I) — and one splice-site variant, IVS17+1g>a.

> "We identified three missense mutations c.2254 C > T [R752C], c. 2177 T > G [I726R], c.2138C > T [T713I] and one splice site mutation [IVS17+1g > a] in the conserved sequence encoding the tyrosine kinase domain of the DDR2 gene." — Bargal et al., PMID: 19110212

The loss-of-function nature and expanding allelic spectrum were reinforced by Akalin et al. (2023), who described three additional patients and confirmed the disorder results from biallelic *DDR2* inactivation. By 2023, ~10 pathogenic *DDR2* variants had been reported (6 missense, 2 nonsense, 1 deletion, 1 splice), consistent with autosomal recessive inheritance.

> "This unique phenotype is caused by biallelic loss-of-function variants in Discoidin domain receptor 2 gene (DDR2, MIM# 191311)." — Akalin et al., PMID: 36720430

Finding 2 — DDR2 loss reduces chondrocyte proliferation, explaining the short-limb dwarfism

The cellular mechanism linking DDR2 loss to the skeletal phenotype was established in mouse models. Labrador et al. (2001) showed that *Ddr2*-deficient mice exhibit dwarfism and shortening of long bones, and — critically — that this results from **reduced chondrocyte proliferation** rather than aberrant differentiation or function.

> "These mice exhibit dwarfism and shortening of long bones. This phenotype appears to be caused by reduced chondrocyte proliferation, rather than aberrant differentiation or function." — Labrador et al., PMID: 11375938

Mohamed et al. (2022) localized DDR2 function to the relevant cell populations, demonstrating selective *Ddr2* expression in resting-zone and proliferating chondrocytes and periosteum, and showing that DDR2 functions in Gli1-positive skeletal progenitors and chondrocytes to control bone development.

> "Expression and lineage analysis showed selective expression of Ddr2 at early stages of bone formation in the resting zone and proliferating chondrocytes and periosteum." — Mohamed et al., PMID: 35140200

A companion study (Mohamed et al., 2023, PMID: 36656123) demonstrated that the shortened skull and flat face of DDR2-mutant mice arise because cranial-base bones fail to elongate due to defects in cartilage-dependent growth centers — providing a direct cellular explanation for the characteristic craniofacial gestalt of SMED-SL/AC.

Finding 3 — Clinical phenotype: distinctive facies, disproportionate short stature, platyspondyly, and premature calcification

The clinical entity was first delineated by Borochowitz (1993), who described a congenital familial skeletal dysplasia with small stature, short limbs and short hands, a short nose with a wide nasal bridge and nostrils, long philtrum, ocular hypertelorism, retro-/micrognathia, and a narrow chest. Radiographs showed platyspondyly, short tubular bones with markedly abnormal metaphyses and epiphyses beyond early infancy, and short ribs, evolving over time.

> "Radiological abnormalities include platyspondyly, short tubular bones with very abnormal metaphyses and epiphyses beyond early infancy, short ribs, and a typical evolution of bony changes over time." — Borochowitz, PMID: 8434618

The disease-defining feature of **premature/abnormal calcification** was emphasized by Mansouri et al. (2016), who noted that it leads to severe disproportionate short stature; approximately 22 patients had been reported in the literature by that time.

> "premature calcification leading to severe disproportionate short stature" — Mansouri et al., PMID: 26463668

Chondro-osseous histopathology reveals sparse cartilage matrix and degenerating chondrocytes surrounded by dense amorphous (calcified) material. Dental anomalies — enamel hypoplasia and abnormal tooth number/shape — have also been described (Akalin et al., 2023, PMID: 36720430), broadening the recognized phenotypic spectrum.

Finding 4 — Allelic contrast: activating DDR2 variants cause Warburg-Cinotti syndrome

DDR2 is a bidirectional signaling node. Whereas loss-of-function alleles cause SMED-SL/AC, recurrent **activating** variants cause a distinct disorder. Xu et al. (2018) identified c.1829T>C (p.Leu610Pro) or c.2219A>G (p.Tyr740Cys) in 6 individuals from 4 families with Warburg-Cinotti syndrome — progressive corneal neovascularization, keloids, chronic skin ulcers, acro-osteolysis, and flexion contractures. Patient fibroblasts showed increased DDR2 phosphorylation, indicating ligand-independent kinase activation; dasatinib inhibited DDR2 autophosphorylation in these cells.

> "Phosphorylation of DDR2 was increased in fibroblasts from affected individuals, suggesting reduced receptor autoinhibition and ligand-independent kinase activation." — Xu et al., PMID: 30449416

This contrast confirms the loss-of-function pathogenesis of SMED-SL/AC and identifies DDR2 as a dose-/activity-sensitive rheostat in connective-tissue biology.

Finding 5 — The DDR2 signaling cascade abolished in SMED-SL/AC

DDR2 is a collagen-activated RTK. Yang et al. (2005) defined its activation mechanism: ligand binding promotes Src-mediated phosphorylation of Tyr-740 in the activation loop, which stimulates intramolecular cis-autophosphorylation and generates cytosolic phosphotyrosines that recruit Shc signaling complexes.

> "ligand binding promotes phosphorylation of Tyr-740 in the DDR2 activation loop by Src; 2) Tyr-740 phosphorylation stimulates intramolecular autophosphorylation of DDR2; 3) DDR2 autophosphorylation generates cytosolic domain phosphotyrosines that promote the formation of DDR2 cytosolic domain-Shc signaling complexe" — Yang et al., PMID: 16186108

Enzyme-kinetic analysis (Hao & Leitinger, 2025) established that wild-type DDR2 kinase follows a two-step activation mechanism analogous to DDR1 but with enhanced autophosphorylation and substrate phosphorylation rates.

> "WT DDR2 kinase was found to follow the same two-step activation mechanism previously characterised for DDR1 kinase but with enhanced autophosphorylation and substrate phosphorylation rates." — Hao & Leitinger, PMID: 41259339

SMED-SL/AC missense variants (R752C, I726R, T713I) and splice/nonsense alleles map to the kinase domain and abolish this signaling (loss of function), whereas activation-loop-region variants (Y740C, L610P) constitutively activate the kinase (Warburg-Cinotti).

Finding 6 — DDR2 domain architecture explains variant effects

DDR2's extracellular region comprises a collagen-binding discoidin (DS) domain plus a DS-like domain; the transmembrane region mediates ligand-independent dimerization and connects via an unusually long juxtamembrane domain to the tyrosine kinase domain (Carafoli & Hohenester, 2013).

> "The extracellular region of DDRs consists of a collagen-binding discoidin (DS) domain and a DS-like domain. The transmembrane region mediates the ligand-independent dimerisation of DDRs and is connected to the tyrosine kinase domain by an unusually long juxtamembrane domain." — Carafoli & Hohenester, PMID: 23128141

The major DDR binding site in fibrillar collagen is the GVMGFO motif (O = hydroxyproline), recognized by an amphiphilic trench at the top of the DS domain.

> "The major DDR binding site in fibrillar collagens is a GVMGFO motif (O is hydroxyproline), which is recognised by an amphiphilic trench at the top of the DS domain." — Carafoli & Hohenester, PMID: 23128141

This architecture explains how SMED-SL/AC variants in functionally distinct regions converge on the same loss-of-function outcome: the discoidin-domain missense R124W (c.370C>T) likely impairs collagen binding, whereas R752C/I726R/T713I lie in the kinase domain and impair catalysis (Mansouri et al., 2016, PMID: 26463668; Bargal et al., 2009, PMID: 19110212).



Figure 1. *Schematic of DDR2 (UniProt Q16832, 855 aa) domain architecture. SMED-SL/AC loss-of-function variants (e.g., discoidin-domain R124W impairing collagen binding; kinase-domain T713I/I726R/R752C impairing catalysis) contrast with Warburg-Cinotti gain-of-function variants (L610P, Y740C) that constitutively activate the kinase. The two disorders represent opposite ends of a single DDR2 activity spectrum.*

Section-by-Section Report

1. Disease Information

Overview. SMED-SL/AC is a congenital autosomal recessive osteochondrodysplasia characterized by severe disproportionate short-limb short stature, distinctive facies, platyspondyly, abnormal metaphyses/epiphyses, and premature (abnormal) calcification of cartilage. It belongs to the spondyloepimetaphyseal dysplasia group, which affects the spine (spondylo-), epiphyses, and metaphyses of long bones.

Key identifiers: - OMIM phenotype: **#271665** (Spondylometaepiphyseal dysplasia, short limb–hand type / SMED short limb–abnormal calcification type) - OMIM gene: ***191311** (*DDR2*) - Orphanet: **ORPHA:1425** - MONDO: **MONDO:0009642** - HGNC (gene): **HGNC:2968**; UniProt Q16832 - ICD-10: within Q77 (osteochondrodysplasia with defects of growth of tubular bones and spine); ICD-11: LD24 range (skeletal dysplasias). No disease-specific MeSH term; indexed under "Osteochondrodysplasias."

Synonyms / alternative names: Spondylo-meta-epiphyseal dysplasia, short limb–hand type (SMED-SL); SMED short limb–abnormal calcification type (SMED-SL/AC); Borochowitz-Cohen-Barak dysplasia type; spondyloepimetaphyseal dysplasia with abnormal calcification.

Information source. All knowledge derives from **aggregated, disease-level resources** — individual case reports and small consanguineous family series (Borochowitz 1993; Bargal 2009; Mansouri 2016; Akalin 2023), plus model-organism and biochemical studies. No EHR-derived or population-registry data exist given the extreme rarity.

2. Etiology

Causal factors. The disease is purely **genetic (monogenic, Mendelian)**: biallelic loss-of-function variants in *DDR2*. No environmental, infectious, or acquired triggers are implicated.

Genetic risk factors. The sole genetic determinant is homozygous or compound-heterozygous pathogenic *DDR2* variation. **Consanguinity** is the principal risk-enabling factor — the founding cohort comprised consanguineous Arab Muslim families, and homozygous variants predominate (PMID: 19110212). No modifier genes or susceptibility loci have been defined.

Environmental risk factors / protective factors. None identified or applicable for this fully penetrant Mendelian disorder. No protective genetic or environmental factors are known.

Gene–environment interactions. Not applicable — no evidence of environmental modification of a monogenic, congenital phenotype.

3. Phenotypes

Phenotype	Type	Suggested HPO term	Onset	Severity	Frequency
Disproportionate short-limb short stature	Physical manifestation	HP:0008873 (Disproportionate short-limb short stature)	Congenital	Severe	Nearly universal
Platyspondyly	Radiographic sign	HP:0000926	Congenital/ infancy	Severe	High
Abnormal metaphyses	Radiographic sign	HP:0000944	Beyond early infancy	Severe	High
Abnormal epiphyses	Radiographic sign	HP:0005930	Beyond early infancy	Severe	High
Premature/ abnormal calcification	Radiographic/ pathologic	HP:0011849 (Abnormal bone ossification); HP:0100670 (Abnormal cartilage matrix)	Congenital	Severe	Disease-defining
Short ribs / narrow chest	Physical/ radiographic	HP:0000774 (Narrow chest); HP:0000772 (Abnormal rib)	Congenital	Moderate–severe	High
Short nose, wide nasal bridge	Facial	HP:0003196; HP:0000431	Congenital	—	Characteristic
Long philtrum	Facial	HP:0000343	Congenital	—	Characteristic
Ocular hypertelorism	Facial	HP:0000316	Congenital	—	Characteristic
Micrognathia/ retrognathia	Facial	HP:0000347	Congenital	—	Characteristic
Short hands (brachydactyly)	Physical	HP:0001156	Congenital	—	Characteristic

Phenotype	Type	Suggested HPO term	Onset	Severity	Frequency
Dental anomalies (enamel hypoplasia, abnormal number/shape)	Physical	HP:0006297; HP:0006482	Childhood	Variable	Reported subset

Progression: Skeletal changes evolve over time ("typical evolution of bony changes"), with metaphyseal/epiphyseal abnormality becoming more marked beyond early infancy (PMID: 8434618).

Quality of life: Severe short stature, skeletal deformity, and narrow chest substantially impair mobility, respiratory reserve, and daily functioning. No formal EQ-5D/SF-36/PROMIS data exist for this ultra-rare disorder.

4. Genetic / Molecular Information

Causal gene: *DDR2* (Discoidin Domain Receptor Tyrosine Kinase 2), chromosome 1q23.3; OMIM *191311; HGNC:2968; UniProt Q16832 (protein, 855 aa).

Pathogenic variants. ~10 reported pathogenic/likely-pathogenic variants (ACMG/AMP). Types include missense (6), nonsense (2), deletion (1), and splice-site (1):

Variant (cDNA)	Protein	Type	Domain	Consequence
c.2254C>T	p.R752C	Missense	Kinase	Loss of catalysis
c.2177T>G	p.I726R	Missense	Kinase	Loss of catalysis
c.2138C>T	p.T713I	Missense	Kinase	Loss of catalysis
IVS17+1g>a	—	Splice	Kinase-encoding	Aberrant splicing / LoF
c.370C>T	p.R124W	Missense	Discoidin (DS)	Impaired collagen binding

(Bargal 2009 PMID: 19110212; Mansouri 2016 PMID: 26463668; Akalin 2023 PMID: 36720430.)

Classification: Pathogenic/likely pathogenic per ACMG. **Allele frequency:** private/extremely rare; absent or near-absent in gnomAD. **Origin:** germline. **Functional consequence:** loss of function (impaired collagen binding or abolished kinase activity). No dominant-negative or gain-of-function effects in SMED-SL/AC (gain-of-function DDR2 instead causes Warburg-Cinotti syndrome).

Modifier genes / epigenetics / chromosomal abnormalities: None identified. This is a single-gene, small-variant disorder without reported cytogenetic changes.

5. Environmental Information

Not applicable. No environmental, lifestyle, or infectious contributors are known for this congenital monogenic disorder.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. Biallelic loss-of-function *DDR2* variant **leads to** a defective DDR2 receptor — either unable to bind fibrillar collagen (DS-domain variant, e.g., R124W) or catalytically dead (kinase-domain variant, e.g., T713I/I726R/R752C; or splice/nonsense allele producing no functional protein).
2. Defective receptor **results in** failure of collagen-induced DDR2 activation: no Src-mediated Tyr-740 phosphorylation, no intramolecular cis-autophosphorylation, and no generation of cytosolic phosphotyrosines (*inferred from the WT activation mechanism defined in PMID: 16186108 and PMID: 41259339*).
3. Loss of DDR2 phosphotyrosines **prevents** recruitment/formation of DDR2–Shc signaling complexes, interrupting downstream proliferative signaling.
4. Interrupted signaling in resting-zone and proliferating growth-plate chondrocytes and Gli1-positive skeletal progenitors **leads to** reduced chondrocyte proliferation (demonstrated in *Ddr2*-null mice, PMID: 11375938).
5. Reduced chondrocyte proliferation **results in** impaired endochondral bone growth at long-bone growth plates and cranial-base synchondroses → **branch A:** shortened long bones/limbs and platyspondyly; **branch B:** failure of cranial-base elongation → flat face, short skull, distinctive facies (PMID: 36656123).
6. Disorganized cartilage with sparse matrix and degenerating chondrocytes **leads to** deposition of dense amorphous material → premature/abnormal calcification (the disease-

defining feature; *the direct mechanistic link between DDR2 loss and ectopic calcification is inferred, not fully demonstrated*).

7. Net result **is** severe disproportionate short-limb short stature, abnormal metaphyses/epiphyses, short ribs/narrow chest, and characteristic craniofacial gestalt.

Molecular pathway. Collagen → DDR2 (RTK) → Src → activation-loop Tyr-740 → autophosphorylation → Shc adaptor complex → proliferative signaling (feeding into downstream MAPK/PI3K effectors typical of RTK signaling). GO annotations: GO:0038063 (collagen-activated tyrosine kinase receptor signaling pathway), GO:0006468 (protein phosphorylation), GO:0008284 (positive regulation of cell population proliferation), GO:0060348 (bone development), GO:0001501 (skeletal system development), GO:0002062 (chondrocyte differentiation).

Cellular processes: growth-plate chondrocyte proliferation (impaired). **Protein dysfunction:** loss of function via impaired ligand binding or catalytic inactivation. **Cell types (CL):** chondrocyte (CL:0000138), specifically resting/proliferating growth-plate chondrocytes; skeletal (Gli1+) progenitor cells; periosteal cells; osteoblast lineage (CL:0000062). **Tissue-damage mechanism:** defective cartilage matrix homeostasis with ectopic calcification.

Molecular profiling / advanced technologies: No human transcriptomic, proteomic, or metabolomic datasets are available for this ultra-rare disease. Mechanistic evidence is drawn from mouse genetics and in-vitro biochemistry/enzyme kinetics.

7. Anatomical Structures Affected

- **Organ/system level:** Skeletal system — long bones (UBERON:0002481 bone tissue; UBERON:0001474 bone element), vertebral column (UBERON:0001130), ribs (UBERON:0002228), skull/cranial base (UBERON:0003128), face. Secondary: respiratory compromise from narrow chest; dentition (enamel).
- **Tissue/cell level:** Cartilage (UBERON:0002418), growth-plate cartilage (UBERON:0006721); connective tissue. Target cells: chondrocytes (CL:0000138), especially resting/proliferating growth-plate chondrocytes; Gli1+ skeletal progenitors; periosteal/osteoblast lineage.
- **Subcellular level:** DDR2 is a plasma-membrane receptor (GO:0005886 plasma membrane; GO:0005887 integral component of plasma membrane). Signaling occurs at the cytoplasmic kinase domain (GO:0004714 transmembrane receptor protein tyrosine kinase activity).
- **Localization:** Bilateral, symmetric involvement of the appendicular and axial skeleton and craniofacial bones.

8. Temporal Development

- **Onset:** Congenital; skeletal and facial abnormalities present at birth, with radiographic metaphyseal/epiphyseal changes becoming marked beyond early infancy.
- **Onset pattern:** Chronic/insidious progression of bony changes.
- **Progression:** "Typical evolution of bony changes over time" (PMID: 8434618); progressive worsening of disproportion and deformity through childhood; lifelong chronic course.
- **Disease course:** Stable-progressive, non-episodic, non-remitting. No spontaneous or treatment-induced remission.
- **Critical periods:** Prenatal and early postnatal growth-plate activity — the window during which DDR2-dependent chondrocyte proliferation shapes skeletal growth.

9. Inheritance and Population

- **Inheritance:** Autosomal recessive.
- **Epidemiology:** Ultra-rare; ~22 patients reported by 2016 (PMID: 26463668), with additional cases since. Precise prevalence/incidence not established (Orphanet class: <1/1,000,000).
- **Penetrance:** Complete (fully penetrant congenital phenotype). **Expressivity:** Relatively consistent core skeletal phenotype with variable additional features (e.g., dental anomalies).
- **Consanguinity:** Major factor; original and several subsequent families were consanguineous, favoring homozygosity for private variants.
- **Founder effects:** Possible within specific consanguineous populations (Arab Muslim, Moroccan, Turkish families reported), though no formal founder haplotype is established. **Carrier frequency:** not quantified; variants are private.
- **Population demographics:** Reported in Middle Eastern/North African and other populations with consanguineous unions. No strong sex bias expected (autosomal recessive). Age distribution: presents from birth.

10. Diagnostics

- **Imaging (primary diagnostic modality):** Skeletal radiographs demonstrate platyspondyly, short tubular bones with abnormal metaphyses/epiphyses, short ribs, and abnormal/premature calcification — the radiographic hallmark (PMID: 8434618).
- **Histopathology:** Chondro-osseous biopsy shows sparse cartilage matrix, degenerating chondrocytes, and surrounding dense amorphous (calcified) material.

- **Genetic testing (confirmatory):** Molecular confirmation via *DDR2* sequencing. **WES/WGS** have been diagnostically decisive (Mansouri 2016 identified a novel *DDR2* variant by WES, PMID: 26463668). Approaches: single-gene *DDR2* sequencing, skeletal-dysplasia gene panels, WES, or WGS. Homozygosity mapping is useful in consanguineous families.
- **Laboratory tests:** No specific biochemical biomarker; routine calcium/phosphate metabolism is generally not diagnostic. No validated circulating biomarker exists.
- **Clinical criteria:** Diagnosis rests on the characteristic clinical–radiographic gestalt plus biallelic *DDR2* variants.
- **Differential diagnosis:** Other spondyloepimetaphyseal and spondylometaphyseal dysplasias, and short-limb chondrodysplasias; distinguished by the abnormal-calcification pattern, characteristic facies, and *DDR2* genotype.
- **Screening:** Carrier and cascade testing in at-risk consanguineous families; prenatal molecular testing where the familial variant is known.

11. Outcome / Prognosis

- **Survival/mortality:** No systematic survival data. Severe short stature with narrow chest may predispose to respiratory complications; overall prognosis depends on severity of thoracic and skeletal involvement.
- **Morbidity/function:** Substantial lifelong disability from short stature, skeletal deformity, and restricted mobility; potential respiratory limitation.
- **Complications:** Restrictive thoracic constraints, orthopedic deformity, and dental problems.
- **Recovery potential:** None — congenital structural disorder; no reversal possible.
- **Prognostic factors:** Degree of thoracic/skeletal involvement; specific variant effect. No validated prognostic biomarkers.

12. Treatment

There is **no disease-specific or curative therapy**. Management is **supportive and multidisciplinary**:

- **Supportive/rehabilitative:** Orthopedic monitoring and interventions for deformity; physical and occupational therapy; respiratory support as needed; dental care. (NCIT-type interventions: NCIT:C15277 Supportive Care; NCIT:C15682 Physical Therapy; NCIT:C157866 Orthopedic Surgery.)
- **Surgical:** Orthopedic corrective procedures individualized to deformity.

- **Pharmacotherapy / advanced therapeutics:** None established. No gene, cell, RNA-based, or targeted therapy exists. Mechanistically, kinase-domain loss-of-function variants would not be amenable to kinase inhibition (in contrast to Warburg-Cinotti's activating variants, where dasatinib inhibited DDR2 autophosphorylation in vitro, PMID: 30449416).
- **Genetic counseling** is a core component of management.
- **Experimental trials:** None registered for SMED-SL/AC.

13. Prevention

- **Primary prevention:** Genetic counseling for consanguineous/at-risk couples; carrier testing.
- **Secondary/tertiary prevention:** Prenatal molecular diagnosis and preimplantation genetic testing where the familial *DDR2* variant is known; early multidisciplinary management to prevent complications (respiratory, orthopedic).
- **Public health:** Awareness of recessive-disease risk in populations with high consanguinity.
- No immunization or behavioral prevention is applicable.

14. Other Species / Natural Disease

- **Taxonomy / orthologs:** Human *DDR2* (NCBI Gene 4921); mouse *Ddr2* (NCBI Gene 18214). DDR2 is highly conserved across vertebrates.
- **Natural animal disease:** The spontaneous mouse mutant *smallie* (*Ddr2^slie^*, a *Ddr2* loss-of-function allele) exhibits dwarfism and skeletal defects, representing a naturally arising animal model. No well-characterized companion-animal or livestock breed disorder is established, though DDR2 loss-of-function phenotypes are expected to be conserved.
- **Comparative biology:** The mouse *Ddr2*-null skeletal and craniofacial phenotype closely parallels human SMED-SL/AC, confirming evolutionary conservation of DDR2's role in chondrocyte proliferation and endochondral bone growth (PMID: 11375938; PMID: 35140200; PMID: 36656123).
- **Transmission:** Not applicable (non-infectious genetic disorder).

15. Model Organisms

- **Mouse (primary model):** *Ddr2*-deficient/knockout and the spontaneous *smallie* (*Ddr2^slie^*) mutant recapitulate dwarfism, shortened long bones, and craniofacial defects. Conditional/lineage models (Gli1-CreER) localize DDR2 function to skeletal progenitors and chondrocytes.

- **Phenotype recapitulation:** Strong — reduced chondrocyte proliferation, shortened long bones, and flat face/short skull mirror human features.
- **Applications:** Established the cellular mechanism (proliferation vs differentiation), cell-of-origin (Gli1+ progenitors, growth-plate chondrocytes), and craniofacial pathogenesis.
- **Limitations:** The abnormal-calcification phenotype and detailed matrix pathology of the human disease are less fully modeled; species differences in growth-plate biology.
- **In vitro / biochemical models:** Recombinant DDR2 kinase enzyme-kinetic assays and patient fibroblasts have defined the two-step activation mechanism and distinguished loss- vs gain-of-function alleles (PMID: 16186108; PMID: 41259339; PMID: 30449416).
- **Resources:** MGI (mouse *Ddr2*), IMPC.

Mechanistic Model / Interpretation

```
  Fibrillar collagen (GVMGFO motif)
             |
             v   [SMED-SL/AC DS-domain variant e.g. R124W blocks binding]
     DDR2 discoidin (DS) domain  --- amphiphilic trench
             |
             v
   DDR2 dimerization (TM) --> long juxtamembrane --> KINASE domain
             |                                       ^
             |   [SMED-SL/AC kinase variants T713I/I726R/R752C, splice -> NO catalysis]
             v
   Src phosphorylates Tyr-740 (activation loop)
             |
             v
   Intramolecular cis-autophosphorylation
             |
             v
   Cytosolic phosphotyrosines --> Shc complex --> proliferative signaling
             |
             v
   Growth-plate chondrocyte PROLIFERATION (resting/proliferating zones;
   Gli1+ progenitors)
             |
   +---------+----------+
   v                    v
Long-bone &          Cranial-base
vertebral growth     synchondrosis growth
   |                    |
   v                    v
Short limbs,          Flat face, short skull,
platyspondyly,        distinctive facies
abnormal meta/epiphyses + premature calcification
```

Loss-of-function (SMED-SL/AC) and **gain-of-function (Warburg-Cinotti)** sit at opposite ends of a single DDR2 activity axis:

Feature	SMED-SL/AC	Warburg-Cinotti syndrome
Mechanism	Loss of function	Gain of function (constitutive)
Representative variants	R124W (DS), T713I/I726R/R752C, IVS17+1g>a (kinase)	L610P, Y740C
Receptor phosphorylation	Absent/reduced	Increased, ligand-independent
Inheritance	Autosomal recessive (biallelic)	Autosomal dominant (recurrent)
Core phenotype	Chondrodysplasia, short limbs, calcification	Corneal neovascularization, keloids, acro-osteolysis
Druggability	Not kinase-inhibitor amenable	Dasatinib inhibits autophosphorylation (in vitro)

Evidence Base

PMID	Title (abbrev.)	Role in this report
8434618	Original SMED short-limb–hand description (Borochowitz)	Defines clinical/radiographic phenotype
19110212	*DDR2* mutations cause SMED (Bargal)	Establishes causal gene & kinase-domain variants
11375938	DDR2 regulates proliferation; elimination → dwarfism	Cellular mechanism (mouse)
35140200	DDR2 in Gli1+ progenitors/chondrocytes	Cell-of-origin localization
36656123	DDR2 controls craniofacial development	Craniofacial pathogenesis
26463668	Novel *DDR2* variant by WES (Mansouri)	Calcification feature; DS-domain variant; WES utility
36720430	Expanded mutational spectrum & dental findings (Akalin)	Biallelic LoF confirmation; dental phenotype
30449416	Activating DDR2 → Warburg-Cinotti (Xu)	Allelic contrast; gain-of-function
16186108	Tyr-740/Src/Shc signaling (Yang)	Defines signaling cascade lost in disease
41259339	DDR2 kinase two-step activation (Hao & Leitinger)	Kinase activation mechanism
23128141	Collagen recognition by DDRs (Carafoli & Hohenester)	Domain architecture; collagen-binding motif
24725424	DDR functions in physiology/pathology (Leitinger)	Slow/sustained activation kinetics context

Evidence source types: **human clinical** (case series, WES/WGS), **model organism** (mouse knockouts, conditional/lineage tracing), **in vitro/biochemical** (kinase kinetics, patient fibroblasts). No omics or computational disease datasets exist for SMED-SL/AC.

Limitations and Knowledge Gaps

1. **Ultra-rarity:** Fewer than ~30 patients reported; epidemiology, prognosis, and natural history rest on small case series and lack registry-scale data.
2. **Calcification mechanism unresolved:** The precise link from DDR2 loss to premature/abnormal calcification (the disease-defining feature) is inferred, not mechanistically demonstrated. How impaired chondrocyte proliferation and disordered matrix lead to ectopic calcification remains open.
3. **Genotype–phenotype correlations:** Too few patients to correlate DS-domain vs kinase-domain variants with severity or specific features (e.g., dental anomalies).
4. **No human molecular profiling:** No transcriptomic, proteomic, or metabolomic data; mechanistic inference relies on mouse and biochemistry.
5. **Downstream effectors beyond Shc** (MAPK/PI3K and how they control chondrocyte cell-cycle) are not fully mapped in the growth-plate context.
6. **Model limitations:** Mouse models capture growth and craniofacial phenotypes but may under-represent the human calcification pathology.

Proposed Follow-up Experiments / Actions

1. **Mechanistic study of calcification:** Use *Ddr2*-null growth-plate chondrocytes and patient-derived iPSC-chondrocyte/organoid models to dissect how DDR2 loss drives ectopic matrix calcification (matrix vesicle biology, ALP activity, Pi/PPi balance).
2. **Functional variant classification:** Systematically express reported *DDR2* variants (DS-domain vs kinase-domain) and quantify collagen binding, autophosphorylation, and downstream signaling to formalize genotype–function correlations.
3. **Patient registry / natural history study:** Establish an international SMED-SL/AC registry to capture prevalence, survival, respiratory outcomes, and the phenotypic spectrum.
4. **Single-cell/spatial transcriptomics of the growth plate** in *Ddr2*-null mice to define the proliferative program lost downstream of DDR2 and identify therapeutic nodes.
5. **Therapeutic exploration:** Because kinase inhibition is not applicable to loss-of-function disease, evaluate pathway-agonist or downstream-restoration strategies (e.g., modulating Shc/MAPK signaling or growth-plate proliferation cues) in models.

6. **Cranial-base and thoracic longitudinal imaging** in patients to define critical intervention windows and respiratory risk.

Report compiled from 6 confirmed findings and 18 reviewed papers across a 5-iteration autonomous investigation. All quoted material is verbatim from cited PubMed abstracts.
